Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Blinded, Controlled Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of a COVID-19 mRNA Vaccine (ZSVG-02-O) in a Healthy Population 18 Years of Age and Older

NCT06113731 is registered in ClinicalTrials.gov with CNBG-Virogin Biotech (Shanghai) Ltd. as lead sponsor.

NCT NCT06113731
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06113731 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Blinded, Controlled Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of a COVID-19 mRNA Vaccine (ZSVG-02-O) in a Healthy Population 18 Years of Age and Older
Lead sponsor
CNBG-Virogin Biotech (Shanghai) Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
July 10, 2023
Completion date
October 31, 2024
Enrollment
980 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2 infection